Mergers Are Bad for Innovation

Mergers tend to reduce overall innovation, making consumers “always worse off after a merger,” says Tommaso Valletti, the European Commission’s Chief Competition Economist.

 

 

״Big Fish Eat Little Fish.” Designed by Pieter Bruegel the Elder, engraved by Pieter van der Heyden and published by Hieronymus Cock in 1557.

As competition authorities and economists worry about the competitive implications of increasingly concentrated markets, horizontal merger reviews should be broadened to include their potential implications for future innovation. So said Tommaso Valletti, the European Commission’s Chief Competition Economist, during a keynote lecture at an antitrust conference at Northwestern University last week.

 

Valletti, an Economics professor at Imperial College Business School and at the University of Rome Tor Vergata, joined the European Commission a year ago. During this time, the European Commission made a number of high-profile decisions, such as leveling a record €2.42 billion antitrust fine on Google, vetoing the proposed merger between Deutsche Boerse and the London Stock Exchange, clearing the now-completed $130 billion merger between Dow Chemical and DuPont (now known as DowDuPont), and launching an investigation of the proposed merger between Bayer and Monsanto.

 

Most of Valletti’s talk during the Searle Center’s 10th Annual Conference on Antitrust Economics and Competition Policy was devoted to the subject of horizontal mergers and their impact on innovation, through the prism of the Dupont-Dow merger, which the EC cleared under the condition that DuPont divest of its global R&D pesticide facilities. It is the first to be cleared of the three mega-mergers that will reduce the number of top firms in the industry from five to three. The other two pending mergers are the Bayer’s planned purchase of Monsanto and ChemChina’s plan to buy Syngenta.

 

Tommaso Valletti

Valletti, who stressed that he was expressing his personal views and that those do not necessarily represent the views of the European Commission or its Directorate-General for Competition, described the stir that the EC’s decision on DowDuPont caused among some economists and antitrust experts in Europe. “Some people said it was a ‘quantum leap.’ Some said it was ‘crystal ball gazing’ by the Commission, or that the Commission is ‘predicting the winner of the 2022 World Cup,’ or that we introduced a new theory of harm based on innovation that had never been done before and that the remedy that we imposed was unprecedented and too far reaching.” 

 

What followed was an examination of the reasons for the EC decision on DowDuPont, the merger’s implications for R&D, and the need for further research on the implications of horizontal mergers for innovation.

 

“The trend in the [agrochemicals] industry is one of increasing consolidation,” said Valletti. “In pesticides, there are about five big firms. If you look at the 1960s, you could count 40 firms. From forty to five is a big change. The causes and consequences of this change are very contested, but it’s a fact that this industry is increasingly concentrated and that this raises concerns in the general policy debate.”

 

“Among the five big firms—DuPont, Dow, Bayer, BASF, and Syngenta—only a few have the capability to do innovation at every stage and in every segment,” explained Valletti. “In this industry, you innovate by developing new active ingredients (AIs), which are used to make formulated products. To introduce an AI is a very costly process. Entry is difficult and takes a lot of time, because regulatory approval takes many years. Innovation in this industry is very important: firms compete by doing R&D and discovering new AIs. It’s a fundamental business strategy.”

 

The parties in the DuPont-Dow merger, he said, “had standard overlaps, both in [existing] products and in the pipeline [for future products]. They also had significant overlaps in the research for new AIs, meaning they had overlaps in fundamental R&D.”

 

The EC’s argument that DuPont should sell major chunks of its pesticide R&D business, added Valletti, hinged on the nature of innovation in the industry, where “firms don’t innovate randomly. Surely there’s a lot of uncertainty in the R&D outcomes, but firms have very precise research targets, and are doing specific research to achieve a certain result.”

 

EC economists, he explained, focused on areas like herbicides and insecticides, where R&D is focused on a number of narrower subcategories. EC economists looked at the research targets DuPont and Dow set for themselves, using internal documents and relying on the same software the firms use to track each other’s competitive abilities and strengths by assessing their rivals’ patents. “The best predictor of what [firms] will be doing 10 years into the future is the current portfolio of the patents they have now.”

 

To conduct a patent analysis, EC economists weighed the number of each firms’ patents with the number of citations. “We dismissed claims we should only use total R&D allocations. It was too rough, too coarse,” he explained. “When we delved into the narrower technological trajectories, there was one firm in particular, DuPont, that was not patenting a lot, but had very successful patents. So what looked at first sight as a 5–to-4 merger was more like a 4-to-3 or a 3-to-2 merger, in some areas. The overlaps in the fundamental R&D capabilities of these firms played an important part in the decision.”

 

What also factored into the decision were internal documents that suggested the companies will cut their scientists by large amounts. “When you see this in internal documents, it’s difficult not to be concerned,” said Valletti.

 

Part of the difficulty in determining the effect of mergers on innovation, argued Valletti, is that IO economists have so far not done enough work on the subject. “There’s a lot of policy work, but there’s very little explicit theoretical work about this. There’s a huge body of research on the relationship between concentration and innovation, and on the relationship between market integration and innovation, but when it comes specifically to mergers and innovation, there’s much less.”

 

In the course of researching this area, Valletti produced two papers (co-written with colleagues Giulio Federico and Gregor Langus) titled “A Simple Model of Mergers and Innovation,” and “Horizontal Mergers and Product Innovation: An Economic Framework.” These papers analyze the impact of a merger on firms’ incentives to innovate and show that in certain markets at least, mergers tend to reduce overall innovation, making consumers “always worse off after a merger.” 

 

He explained that he and his co-authors found two major forces that can explain the effects of a merger on innovation. On the one hand, firms capture market shares away from rivals by innovating. By merging, a firm would not want to compete against itself, and thus would innovate less. On the other hand, the ability to coordinate product prices after a merger might give an extra incentive to innovate. The models Valletti and his co-authors chose to focus on are ones where product market competition serves as a countervailing force, and yet, “it’s never enough to counteract reductions in innovation by the merging firms.” Following mergers, they found, merging firms have less incentives to innovate.

 

Valletti concluded by calling on economists to conduct further research on the impact of mergers on innovation. “Both in our academic work and in our policy work, we need to look beyond standard current overlaps, or immediate overlaps arising from research pipelines,” said Valletti. “We need to look also the nature of future competition between the merging companies on the basis of their R&D activities and innovation capabilities.”

 

Industries where this expanded framework would naturally apply, said Valletti, are industries where innovation serves as an “important competition parameter” and where patent protection in effect guarantees appropriability, such as tech or pharmaceuticals. “An industry that to me is a natural candidate is the pharmaceutical industry, where often prices are regulated by health authorities or some public body, and so the product market’s effect as a countervailing force is diminished, compared to impact arising from diminished innovation competition.”

  

Disclaimer: The ProMarket blog is dedicated to discussing how competition tends to be subverted by special interests. The posts represent the opinions of their writers, not those of the University of Chicago, the Booth School of Business, or its faculty. For more information, please visit ProMarket Blog Policy. 

One comment

  1. It is certainly true to say that mergers among competing businesses in a free market economy has the negative effect of discouraging the essential practice of innovation – in addition to dissuading businesses from spending their own money on research & development, the creation of intellectual property and up-skilling of employees.

    What is also undeniable is the fact that, the type of competition used by the buyer to purchase goods, services and labour is the single most important factor that determines if value for money will be obtained, or not – especially so, if that buyer is the Government itself which, as a rule, always spends more than any other entity in all countries around the world.

    Central to any good competitive process is what some Governments call ‘keeping up competitive tension’ between suppliers throughout the entire period of the competition. This is just another way of saying that all Bidders should ‘feel the heat’ of competitive market forces – from the time the Government engages with the market for the provision of goods, services or labour, to the moment the single Bidder is selected, as the preferred Contractor to receive the contract.

    Whatever it is called, it is certainly not happening in the UK during the ‘sudden death’ competition (which reduces the field of Bidders from six to one following a one-off release of the invitation to tender, as shown in this illustration pic.twitter.com/xk0d8phEAJ) currently used by the Ministry of Defence to procure military equipment for the Armed Forces.

    No least because the presently applied ‘sudden death’ competition used by MoD has been rendered ineffective by Defence Contractors, who are quoting identical bottom-line Selling Prices against the same requirement – which amounts to price-fixing on a grand scale, with the active connivance of the Secretary of State for Defence. Worse still, MoD’s Project Team Leader is being denied the opportunity to choose the single Contractor on the basis of price competitiveness, and therefore value for money.

    This has come about because MoD’s long-standing policy of disclosing the total budgeted expenditure figure or associated year-on-year financial funding profile in the ITT has resulted in Defence Contractors quoting identical bottom-line Selling Prices in their ITT responses – an entirely predictable result!

    What’s more, the single Contractor has no incentive to perform or keep prices down the moment all five Competitors disappear suddenly, which would explain why defence equipment procurement programmes have been plagued by persistent delays and cost over-runs, for as long anyone can remember.

    It is precisely to avoid this sort of disastrous situation from arising that the Government should do the sensible thing and quietly retire this tried-and-failed competition policy and instead, set the objective of selecting the winning Contractor from a choice of industry teams, by running a multiple-phase winner-takes-all competition on the basis of a level playing field genuinely open to all-comers, including non-domiciled suppliers – to make sure it gets the very best value for money for the taxpayer.

    Using the market-based instrument of open competition to select a single Contractor has the beneficial effect of incentivising all Bidders to get serious about identifying, quantifying and controlling the prime equipment and its associated Support Assets costs – a process that begins at the time of preparing the response to the ITT for the first Contract performance phase. Bidders who fail to do so run the risk of being excluded from the next phase of the competition.

    Normal commercial pressures and market forces inherent within the context of a multiple-phase winner-takes-all competition will, in themselves, compel Bidders to produce and deliver competitively priced, fully compliant ITT responses – not, because the Government says so, as people in the pay of the State seem to think, but because of the omnipresent threat from the Competition!

    The policy of Progressive Elimination – removing Bidders one-by-one during the winner-takes-all competition requires that, a Bidder who scores worst against the selection criteria should be eliminated immediately after the Project Delivery Team has taken receipt of ITT responses and another, who has performed least well, at the end of each Contract performance phase, as shown in this second illustration pic.twitter.com/RUToAZ6thx.

    That is to say:

    (a) From seven Bidders to five immediately after taking receipt of responses to the ITT for the first Contract performance phase.

    (b) From five to four at the end of the first Contract performance phase.

    (c) From four to three immediately after taking receipt of responses to the revised ITT for the second Contract performance phase.

    (d) From three to two at the end of the second Contract performance phase.

    (e) And finally, from two to one after taking receipt of responses to the revised ITT for the final manufacture and in-service sustainment phase.

    The ultimate result is one winner and six losers at the end of the multiple-phase competition.

    Another beneficial side-effect of applying this fully inclusive, winner-takes-all competition policy is that it will remove long-standing distortions and inefficiencies in the Supply Chain – by identifying and rooting out those Subcontractors who have positioned themselves in the extended Supply Chain but are not actually adding any value, that is to say, people who are acting as middle-men by simply raising invoices against the value of goods and services produced by lower-level, small and medium-sized enterprises suitably marked-up to reflect their cut of the action!
    @JagPatel3 on twitter

Leave a Reply